title: Concurrent ganirelix and follitropin beta therapy is an effective and safe regimen for ovulation induction in women with polycystic ovary syndrome.
abstract: OBJECTIVE
  To evaluate controlled ovarian stimulation cycles using the GnRH antagonist ganirelix in combination with the recombinant FSH, follitropin-beta, in women with polycystic ovary syndrome (PCOS).
  
  
  METHODS
  Prospective, nonrandomized clinical study.
  
  
  METHODS
  Hospital-based infertility practice.
  
  
  METHODS
  Twenty women with PCOS planning to undergo ovarian stimulation.
  
  
  METHODS
  Fasting glucose and insulin levels were used to calculate insulin resistance ratios (FG/I). After pretreatment with oral contraceptives, serum LH levels were determined, and 250 microg ganirelix was administered on cycle day 2. Upon suppression of LH, concurrent ganirelix and follitropin-beta therapy (morning ganirelix and evening follitropin-beta) was started and continued until the day of hCG.
  
  
  METHODS
  Days of stimulation, dose of follitropin-beta, pregnancy, and ongoing pregnancy were compared based on FG/I ratios.
  
  
  RESULTS
  One dose of ganirelix effectively suppressed LH levels in all patients. All patients ovulated as documented by a rise in progesterone. Significant differences were observed between the insulin-resistant and non-insulin-resistant groups for both days of stimulation and dose of follitropin-beta. The overall clinical pregnancy rate was 44.4%, with an ongoing pregnancy rate of 27.8%.
  
  
  CONCLUSIONS
  In this preliminary study, we demonstrate the effectiveness of a concurrent ganirelix and follitropin-beta therapy for ovarian stimulation in women with PCOS.
authors.affiliation: Woman's Health Research Institute, Woman's Hospital, Baton Rouge, Louisiana 70810, USA. keh@womans.com
authors.forename: Karen E
authors.initials: KE
authors.lastname: Elkind-Hirsch
authors.forename: Bobby W
authors.initials: BW
authors.lastname: Webster
authors.forename: Crystal P
authors.initials: CP
authors.lastname: Brown
authors.forename: Michael W
authors.initials: MW
authors.lastname: Vernon
mesh_terms: D001786:Blood Glucose / Q000032:analysis; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D005215:Fasting; D005260:Female; D037201:Follicle Stimulating Hormone, beta Subunit / Q000008:administration & dosage*; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors; D006727:Hormone Antagonists / Q000008:administration & dosage; D006801:Humans; D007247:Infertility, Female / Q000209:etiology / Q000628:therapy; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D007986:Luteinizing Hormone / Q000097:blood; D010062:Ovulation Induction / Q000379:methods*; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000628:therapy*; D011247:Pregnancy; D011446:Prospective Studies
chemical_list: D001786:Blood Glucose; D006063:Chorionic Gonadotropin; D037201:Follicle Stimulating Hormone, beta Subunit; D006727:Hormone Antagonists; D007328:Insulin; D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone; C061018:ganirelix